Global Cannabis Regulatory Summit Announced by Artemis Growth Partners
Artemis Growth Partners announced the first Global Cannabis Regulatory Summit taking place in March 2025.
Image | adobe.stock/kasto
Artemis Growth Partners announced in a recent press release that the investment group would be partnering with Tenacious Labs to host the first Global Cannabis Regulatory Summit (GCRS). This event will take place at the United States Capitol Complex during March 26-27, 2025. The summit hopes to encourage “global connectivity and partnership amongst regulators, industry, and investors,” (1).
Anticipated for 2025, global cannabis sales within regulated markets are predicted to climb to $51 billion, according to New Frontier Data (2). Attendees at the Global Cannabis Regulatory Summit will include international policy experts, industry executives, and members of Congress (1). In the press release, it mentions that at the event (1) “…ideas will be shared and discussed in an effort to expedite the momentum of cannabis legalization in different jurisdictions and its potential to foster global development.” Attendees will be able to network with international regulators, as well as others within the cannabis industry, and be able to learn from other’s experiences to help grow the industry.
On the night of March 25, 2025, a reception will be held and then on March 26, 2025, the first day of the summit will consist of informative panel discussions on a variety of topics such as, the medical cannabis market. A dinner where attendees will be able to network, will be hosted after the event (1). For day two of the summit, there will be panels covering subjects such as (1), “Cannabis in the Americas, Moving from Prohibition to Regulation in Europe, Emerging and New Sovereign Markets/Rest of World and Unlocking Global Economic Growth.”
“After much research and hard work, we are thrilled to finally be able to provide a crucially needed space for regulators and experts of the highest levels to convene and discuss the outlook of the global cannabis market,” Will Muecke, co-founder and chief investment officer of Artemis Growth Partners, said (1).
Muecke further mentioned in the press release (1), “As legislation evolves and markets come online at different paces all over the world, it is becoming clearer that an interconnected supply chain of both product and capital will prove vital for long-term growth, sustainability and patient benefit. The Global Cannabis Regulatory Summit aims to be the setting for the pivotal connections that will shape the future. We hope that the success of the summit this year will make the GCRS an annual must-attend event for regulators, industry players, and investors in cannabis operators.”
References
- Artemis Growth Partners. Artemis Growth Partners announce inaugural Global Cannabis Regulatory Summit https://www.prnewswire.com/news-releases/artemis-growth-partners-announce-inaugural-global-cannabis-regulatory-summit-302370343.html (accessed Feb 12, 2025).
- New Frontier Data Projects Doubling of global legal cannabis sales to USD $51B by 2025 https://newfrontierdata.com/cannabis-insights/new-frontier-data-projects-doubling-of-global-legal-cannabis-sales-to-usd-51b-by-2025/ (accessed Feb 12, 2025).
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
